Keywords
Haemophilia A
Inhibitors
Emicizumab
Inhibitors
Emicizumab
How to Cite
Pinto, I. S. (2023). Zero bleeds in a hemophiliac with severe hemorragic profile in the induction phase of emicizumabe: a case report. JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA, 1(s1). Retrieved from https://ojs.jaff.org.br/ojs/index.php/jaff/article/view/246
Abstract
Hemophilia A is an inherited bleeding disorder caused by a deficiency in the clotting protein factor VIII (FVIII). Inhibitor development is the burden treatment complication seen in patients with hemophilia since these antibodies inactivate FVIII. Until recently, patients were treated with bypassing agents, that are not as effective as FVIII replacement. The only proven method for eradication is immune tolerance induction (ITI). Since the year of 2021, Emicizumabe, a bispecific monoclonal antibody factor VIII mimetic was approved in Brazil to patients with inhibitors who had failed ITI. Now we present a case report of a hemophilia A patient, with a severe bleeding phenotype, who had inhibitor recurrence after successful ITI, who was the first person to be treated with Emicizumabe on the Hemophilia Treatment Center (HTC) in the state of Pará, whose quick response surprised us.Todo o conteúdo dos artigos publicados no JAFF está licenciado sob uma Licença Creative Commons Atribuição 4.0 Internacional, que permite o uso, compartilhamento, adaptação, distribuição e reprodução em qualquer meio ou formato, desde que você dê o devido crédito ao autor(es) original(ais) e a fonte, fornecer um link para a licença Creative Commons e indicar se alterações foram feitas. As imagens ou outros materiais de terceiros neste artigo estão incluídos na licença Creative Commons do artigo, salvo indicação em contrário em uma linha de crédito para o material.